Announcement • Aug 03
Anuh Pharma Limited to Report Q1, 2027 Results on Aug 07, 2026 Anuh Pharma Limited announced that they will report Q1, 2027 results on Aug 07, 2026 Upcoming Dividend • Jul 29
Upcoming dividend of ₹1.50 per share Eligible shareholders must have bought the stock before 05 August 2026. Payment date: 11 September 2026. Payout ratio is a comfortable 37% but the company is not cash flow positive. Trailing yield: 1.9%. Within top quartile of Indian dividend payers (1.4%). Higher than average of industry peers (0.7%). Reported Earnings • Jul 22
Full year 2026 earnings released: EPS: ₹4.10 (vs ₹9.45 in FY 2025) Full year 2026 results: EPS: ₹4.10 (down from ₹9.45 in FY 2025). Revenue: ₹7.72b (up 17% from FY 2025). Net income: ₹410.5m (down 13% from FY 2025). Profit margin: 5.3% (down from 7.2% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth. Declared Dividend • May 23
Dividend of ₹1.50 announced Shareholders will receive a dividend of ₹1.50. Ex-date: 5th August 2026 Payment date: 11th September 2026 Dividend yield will be 2.0%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (16% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 7.6% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • May 22
Full year 2026 earnings released: EPS: ₹4.10 (vs ₹4.73 in FY 2025) Full year 2026 results: EPS: ₹4.10 (down from ₹4.73 in FY 2025). Revenue: ₹7.76b (up 17% from FY 2025). Net income: ₹410.5m (down 13% from FY 2025). Profit margin: 5.3% (down from 7.2% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. Reported Earnings • Feb 07
Third quarter 2026 earnings released: EPS: ₹1.34 (vs ₹1.03 in 3Q 2025) Third quarter 2026 results: EPS: ₹1.34 (up from ₹1.03 in 3Q 2025). Revenue: ₹2.01b (up 26% from 3Q 2025). Net income: ₹134.5m (up 30% from 3Q 2025). Profit margin: 6.7% (up from 6.5% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 08
Second quarter 2026 earnings released: EPS: ₹0.76 (vs ₹1.50 in 2Q 2025) Second quarter 2026 results: EPS: ₹0.76 (down from ₹1.50 in 2Q 2025). Revenue: ₹1.87b (up 13% from 2Q 2025). Net income: ₹76.1m (down 49% from 2Q 2025). Profit margin: 4.1% (down from 9.1% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Aug 26
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹8.77b (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₹8.77b market cap, or US$100.0m). Upcoming Dividend • Aug 07
Upcoming dividend of ₹1.50 per share Eligible shareholders must have bought the stock before 14 August 2025. Payment date: 21 September 2025. Payout ratio is a comfortable 16% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of Indian dividend payers (1.3%). In line with average of industry peers (0.8%). Reported Earnings • Jul 31
Full year 2025 earnings released: EPS: ₹4.73 (vs ₹5.99 in FY 2024) Full year 2025 results: EPS: ₹4.73 (down from ₹5.99 in FY 2024). Revenue: ₹6.62b (up 2.2% from FY 2024). Net income: ₹473.5m (down 21% from FY 2024). Profit margin: 7.2% (down from 9.3% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 25% per year. New Risk • Jul 14
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹5.19b (US$60.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₹5.19b market cap, or US$60.4m). Announcement • May 26
Anuh Pharma Limited, Annual General Meeting, Aug 22, 2025 Anuh Pharma Limited, Annual General Meeting, Aug 22, 2025. Declared Dividend • May 26
Dividend reduced to ₹1.50 Dividend of ₹1.50 is 40% lower than last year. Ex-date: 14th August 2025 Payment date: 21st September 2025 Dividend yield will be 0.7%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by both earnings (21% earnings payout ratio) and cash flows (74% cash payout ratio). The dividend has increased by an average of 8.7% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 27% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • May 24
Full year 2025 earnings released: EPS: ₹9.45 (vs ₹11.99 in FY 2024) Full year 2025 results: EPS: ₹9.45 (down from ₹11.99 in FY 2024). Revenue: ₹6.71b (up 3.7% from FY 2024). Net income: ₹473.5m (down 21% from FY 2024). Profit margin: 7.1% (down from 9.3% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 23
Anuh Pharma Limited Proposes Dividend for Financial Year Ended March 31, 2025 Anuh Pharma Limited at its board meeting held on 23 May 2025 recommended dividend of INR 1.50 per Equity share on post-bonus share capital, amounting to a 30% payout on the face value of INR 5 each for the Financial Year ended 31st March, 2025. The proposed dividend is subject to Shareholder's approval at the upcoming Annual General Meeting (AGM) of the Company. Announcement • May 19
Anuh Pharma Limited to Report Q4, 2025 Results on May 23, 2025 Anuh Pharma Limited announced that they will report Q4, 2025 results on May 23, 2025 Valuation Update With 7 Day Price Move • May 19
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹203, the stock trades at a trailing P/E ratio of 20.3x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 113% over the past three years. Valuation Update With 7 Day Price Move • Apr 03
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₹183, the stock trades at a trailing P/E ratio of 18.3x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 88% over the past three years. New Risk • Feb 14
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹8.45b (US$97.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (dividend per share is over 5x cash flows per share). Large one-off items impacting financial results. Market cap is less than US$100m (₹8.45b market cap, or US$97.4m). Valuation Update With 7 Day Price Move • Feb 14
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹169, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 73% over the past three years. Reported Earnings • Feb 08
Third quarter 2025 earnings released: EPS: ₹2.06 (vs ₹3.81 in 3Q 2024) Third quarter 2025 results: EPS: ₹2.06 (down from ₹3.81 in 3Q 2024). Revenue: ₹1.60b (down 6.8% from 3Q 2024). Net income: ₹103.4m (down 46% from 3Q 2024). Profit margin: 6.4% (down from 11% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 27% per year whereas the company’s share price has increased by 24% per year. Announcement • Jan 31
Anuh Pharma Limited to Report Q3, 2025 Results on Feb 07, 2025 Anuh Pharma Limited announced that they will report Q3, 2025 results on Feb 07, 2025 Reported Earnings • Nov 09
Second quarter 2025 earnings released: EPS: ₹3.00 (vs ₹2.76 in 2Q 2024) Second quarter 2025 results: EPS: ₹3.00 (up from ₹2.76 in 2Q 2024). Revenue: ₹1.69b (up 13% from 2Q 2024). Net income: ₹150.4m (up 8.7% from 2Q 2024). Profit margin: 8.9% (down from 9.3% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Announcement • Oct 31
Anuh Pharma Limited to Report Q2, 2025 Results on Nov 08, 2024 Anuh Pharma Limited announced that they will report Q2, 2025 results on Nov 08, 2024 Recent Insider Transactions • Sep 05
Insider recently sold ₹726k worth of stock On the 30th of August, Bijal Shroff sold around 4k shares on-market at roughly ₹203 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹3.0m more than they bought in the last 12 months. Announcement • Aug 22
Anuh Pharma Limited Announces Cessation of Sandeep Madhusudan Joshi as Independent Director Anuh Pharma Limited announced that Mr. Sandeep Madhusudan Joshi has completed his second and final term as an independent director and consequently ceased to be a director of the company with effect from the closure of business hours on 21 August 2024. Valuation Update With 7 Day Price Move • Aug 16
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹199, the stock trades at a trailing P/E ratio of 17.2x. Average trailing P/E is 36x in the Pharmaceuticals industry in India. Total returns to shareholders of 75% over the past three years. Upcoming Dividend • Aug 09
Upcoming dividend of ₹2.50 per share Eligible shareholders must have bought the stock before 16 August 2024. Payment date: 22 September 2024. Payout ratio is a comfortable 21% but the company is paying out more than the cash it is generating. Trailing yield: 1.0%. Lower than top quartile of Indian dividend payers (1.1%). Higher than average of industry peers (0.7%). Reported Earnings • Aug 04
Full year 2024 earnings released: EPS: ₹11.99 (vs ₹7.22 in FY 2023) Full year 2024 results: EPS: ₹11.99 (up from ₹7.22 in FY 2023). Revenue: ₹6.47b (up 23% from FY 2023). Net income: ₹600.6m (up 66% from FY 2023). Profit margin: 9.3% (up from 6.9% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Announcement • Aug 02
Anuh Pharma Limited to Report Q1, 2025 Results on Aug 09, 2024 Anuh Pharma Limited announced that they will report Q1, 2025 results on Aug 09, 2024 Announcement • May 23
Anuh Pharma Limited, Annual General Meeting, Aug 23, 2024 Anuh Pharma Limited, Annual General Meeting, Aug 23, 2024. Declared Dividend • May 20
Dividend increased to ₹2.50 Dividend of ₹2.50 is 25% higher than last year. Ex-date: 16th August 2024 Payment date: 22nd September 2024 Dividend yield will be 1.0%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (28% earnings payout ratio) but not covered by cash flows (127% cash payout ratio). The dividend has increased by an average of 7.2% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 21% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • May 18
Full year 2024 earnings released: EPS: ₹11.98 (vs ₹7.22 in FY 2023) Full year 2024 results: EPS: ₹11.98 (up from ₹7.22 in FY 2023). Revenue: ₹6.59b (up 25% from FY 2023). Net income: ₹600.6m (up 66% from FY 2023). Profit margin: 9.1% (up from 6.9% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Announcement • May 18
Anuh Pharma Limited Recommends Dividend for the Financial Year Ended 31 March 2024 Anuh Pharma Limited announced that at its board meeting held on 17 May 2024, the board recommended the payment of dividend of INR 2.50 per equity share of face value of INR 5 each (that is 50%) for the financial year ended 31 March 2024, subject to the approval of the Shareholders at the upcoming Annual General Meeting of the Company. register of members and share transfer books of the company will remain closed from 17 August 2024 to 23 August 2024 (both days inclusive) for the purpose of dividend, if approved by members. Announcement • May 11
Anuh Pharma Limited to Report Fiscal Year 2024 Results on May 17, 2024 Anuh Pharma Limited announced that they will report fiscal year 2024 results on May 17, 2024 Announcement • Apr 04
Anuh Pharma Limited Appoints Manan Jayesh Vadhan as Company Secretary and Compliance Officer Anuh Pharma Limited at its board meeting held on April 4, 2024, approved the appointment of Mr. Manan Jayesh Vadhan as the Company Secretary and Compliance Officer of the Company and shall be Designated as the Key Managerial Personnel of the Company with effect from April 4, 2024. Mr. Manan Jayesh Vadhan is a Qualified Company Secretary (Membership No. A69397) And having over 4 years of versatile & diversified experience in Corporate Laws, Corporate actions, Secretarial and Legal Compliances of Listed Companies, Public, Private Companies And LLP's as well. Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹249, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 188% over the past three years. Valuation Update With 7 Day Price Move • Feb 16
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹207, the stock trades at a trailing P/E ratio of 19.1x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 95% over the past three years. New Risk • Feb 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (95% cash payout ratio). Share price has been volatile over the past 3 months (7.7% average weekly change). Announcement • Feb 12
Anuh Pharma Limited Announces Resignation of Jinal Dharmil Mehtalia as Company Secretary and Compliance Officer, Effective 14 February, 2024 Anuh Pharma Limited announced that Ms. Jinal Dharmil Mehtalia has tendered resignation from the post of Company Secretary and Compliance Officer of the Company, due to personal reasons with effect from 14 February, 2024. Reported Earnings • Feb 11
Third quarter 2024 earnings released: EPS: ₹3.81 (vs ₹1.86 in 3Q 2023) Third quarter 2024 results: EPS: ₹3.81 (up from ₹1.86 in 3Q 2023). Revenue: ₹1.76b (up 27% from 3Q 2023). Net income: ₹191.1m (up 105% from 3Q 2023). Profit margin: 11% (up from 6.7% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Announcement • Feb 02
Anuh Pharma Limited to Report Q3, 2024 Results on Feb 09, 2024 Anuh Pharma Limited announced that they will report Q3, 2024 results on Feb 09, 2024 Announcement • Jan 11
Anuh Pharma Limited Announces the Resignation of Hemant Aunt as Company Secretary and Compliance Officer Anuh Pharma Limited announced the Resignation of Hemant Aunt as Company Secretary and Compliance Officer of the company, effective from January 11, 2023. Announcement • Jan 05
Anuh Pharma Limited Announces Appointment of Ms. Jinal Ajay Shah as Company Secretary and Compliance Officer, Effective from 15 January 2024 Anuh Pharma Limited announced the appointment of Ms. Jinal Ajay Shah as Company Secretary and Compliance Officer, Effective from 15 January 2024. Ms. Jinal Ajay Shah is a Qualified Company Secretary having Membership no. A44250 and having over 7 years of versatile & diversified experience in Corporate Laws, Corporate actions, Secretarial and Legal Compliances of Listed Companies, Public and Private Companies as well. Announcement • Dec 13
Anuh Pharma Limited Approves the Board Appointments Anuh Pharma Limited approved the appointment of Mr. Pradeep Thakur (DIN: 00685992) as an Additional Director (Non-Executive, Independent Director) of the Company for a First term of 5 (Five) consecutive years effective from 1st April, 2024 to 31st March, 2029. Mr. Pradeep Thakur is a Post Graduate in Chemistry from Mumbai University and has Diploma in Export Management. He has studied "Masters in Administrative Management" at Jamnalal Bajaj Institute of Management studies, Mumbai. He has more than 30 years of working experience in Chemical and Pharmaceutical Industry in various functions like Process Development, Quality control, Quality Assurance, Business Development and General Administration. He has in the past worked with Bayer India, Anamed Instruments, Cipla Ltd, Dr. Reddy's Labs, Schweizerhall India and Aceto Pharma India Private Limited in various positions. His last assignment was with Aceto Pharma India Pvt. Limited as a Managing Director. The board approved the appointment of Mr. Siddharth Shah (DIN: 00004958) as an Additional Director (Non-Executive, Independent Director) of the Company for a First term of 5 (Five) consecutive years effective from 1st April, 2024 to 31st March, 2029. Mr. Siddharth Shah holds a degree in Civil Engineering, Master in Business Administration and a Diploma in Securities Law. He has been on the Board of Directors of various Market Infrastructure Companies such as Bombay Stock Exchange (BSE), Central Depositories Services Ltd. (CDSL) and BOI Shareholding Ltd. (a JV between BSE and Bank of India). He has a vast experience of nearly 33 years in the financial markets and numerous technology based platforms. He was instrumental in many landmark projects like Online Trading platform of BSE, Demutualization and Corporatization of BSE, Listing of BSE, among others. He held the leadership role as Chairman of BSE Brokers Forum (an Industry body of more than 1,000 brokers). He is currently the CEO of his 3rd generation family run brokerage house dealing in various investment verticals. Valuation Update With 7 Day Price Move • Nov 17
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹160, the stock trades at a trailing P/E ratio of 18x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 19% over the past three years. Reported Earnings • Nov 16
Second quarter 2024 earnings released: EPS: ₹2.76 (vs ₹1.98 in 2Q 2023) Second quarter 2024 results: EPS: ₹2.76 (up from ₹1.98 in 2Q 2023). Revenue: ₹1.50b (up 30% from 2Q 2023). Net income: ₹138.3m (up 40% from 2Q 2023). Profit margin: 9.3% (up from 8.6% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Announcement • Nov 04
Anuh Pharma Limited to Report Q2, 2024 Results on Nov 10, 2023 Anuh Pharma Limited announced that they will report Q2, 2024 results on Nov 10, 2023 Announcement • Aug 20
Anuh Pharma Limited Approves Board Appointments Anuh Pharma Limited at its Annual general meeting held on August 18, 2023, approved the appointment of Mr. Pradeep Thakur (DIN: 00685992) as an Additional Director (Non-Executive, Independent Director) of the Company for a First term of 5 (Five) consecutive years effective from 1st April, 2024 to 31st March, 2029; Appointment of Mr. Siddharth Shah (DIN: 00004958) as an Additional Director (Non-Executive, Independent Director) of the Company for a First term of 5 (Five) consecutive years effective from 1st April, 2024 to 31st March, 2029; Mr. Pradeep Thakur is a Post Graduate in Chemistry from Mumbai University and has Diploma in Export Management. He has studied "Masters in Administrative Management" at Jamnalal Bajaj Institute of Management studies, Mumbai. He has more than 30 years of working experience in Chemical and Pharmaceutical Industry in various functions like Process Development, Quality control, Quality Assurance, Business Development and General Administration. He has in the past worked with Bayer India, Anamed Instruments, Cipla Ltd, Dr. Reddy's Labs, Schweizerhall India and Aceto Pharma India Private Limited in various positions. His last assignment was with Aceto Pharma India Pvt. Limited as a Managing Director. Mr. Siddharth Shah holds a degree in Civil Engineering, Master in Business Administration and a Diploma in Securities Law. He has been on the Board of Directors of various Market Infrastructure Companies such as Bombay Stock Exchange (BSE), Central Depositories Services Ltd. (CDSL) and BOI Shareholding Ltd. (a JV between BSE and Bank of India). He has a vast experience of nearly 33 years in the financial markets and numerous technology based platforms. He was instrumental in many landmark projects like Online Trading platform of BSE, Demutualization and Corporatization of BSE, Listing of BSE, among others. He held the leadership role as Chairman of BSE Brokers Forum (an Industry body of more than 1,000 brokers). He is currently the CEO of his 3rd generation family run brokerage house dealing in various investment verticals. New Risk • Aug 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (₹6.89b market cap, or US$83.4m). Announcement • Aug 04
Anuh Pharma Limited to Report Q1, 2024 Results on Aug 11, 2023 Anuh Pharma Limited announced that they will report Q1, 2024 results on Aug 11, 2023 Upcoming Dividend • Aug 04
Upcoming dividend of ₹2.00 per share at 1.5% yield Eligible shareholders must have bought the stock before 11 August 2023. Payment date: 17 September 2023. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 1.5%. Within top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.9%). Reported Earnings • Jul 28
Full year 2023 earnings released: EPS: ₹7.22 (vs ₹6.10 in FY 2022) Full year 2023 results: EPS: ₹7.22 (up from ₹6.10 in FY 2022). Revenue: ₹5.27b (up 8.4% from FY 2022). Net income: ₹361.8m (up 18% from FY 2022). Profit margin: 6.9% (up from 6.3% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Announcement • Jul 26
Anuh Pharma Limited, Annual General Meeting, Aug 10, 2023 Anuh Pharma Limited, Annual General Meeting, Aug 10, 2023. Location: Hall of Harmony, Nehru Centre, Dr. Annie Besant Road, Worli, Mumbai Mumbai India Agenda: To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended March 31, 2023, including Audited Balance Sheet as on March 31, 2023 and the Statement of Profit & Loss for the year ended on that date together with the Reports of the Board of Directors and Auditors thereon for the said year; to declare a final Dividend; to appoint a Director in place of Mr. Bipin N. Shah who retires by rotation and, being eligible offer himself for re-appointment; and to consider other matters. Valuation Update With 7 Day Price Move • Jun 14
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₹113, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 2.9% over the past three years. Reported Earnings • May 20
Full year 2023 earnings released: EPS: ₹7.22 (vs ₹6.10 in FY 2022) Full year 2023 results: EPS: ₹7.22 (up from ₹6.10 in FY 2022). Revenue: ₹5.34b (up 9.6% from FY 2022). Net income: ₹361.8m (up 18% from FY 2022). Profit margin: 6.8% (up from 6.3% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Announcement • May 13
Anuh Pharma Limited to Report Q4, 2023 Results on May 19, 2023 Anuh Pharma Limited announced that they will report Q4, 2023 results on May 19, 2023 Reported Earnings • Feb 12
Third quarter 2023 earnings released: EPS: ₹1.86 (vs ₹1.49 in 3Q 2022) Third quarter 2023 results: EPS: ₹1.86 (up from ₹1.49 in 3Q 2022). Revenue: ₹1.39b (up 5.4% from 3Q 2022). Net income: ₹93.1m (up 25% from 3Q 2022). Profit margin: 6.7% (up from 5.7% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Announcement • Feb 11
Anuh Pharma Limited Announces Resignation of Lalitkumar P Shah as Non-Executive Director Anuh Pharma Limited announced that Mr. Lalitkumar P Shah, Non-Executive Director of the company has vide his resignation letter dated February 10, 2023, resigned from the Board of the Company with immediate effect. Reason for change is due to ill health and age of 88 years. Announcement • Feb 04
Anuh Pharma Limited to Report Q3, 2023 Results on Feb 10, 2023 Anuh Pharma Limited announced that they will report Q3, 2023 results on Feb 10, 2023 Announcement • Jan 07
Anuh Pharma Limited Approves Appointment of Hemant Auti as the Company Secretary & Compliance Officer Anuh Pharma Limited announced that at its board meeting held on 6 January 2023, approved appointment of Mr. Hemant Auti as the company secretary & compliance officer and designated him as a key managerial personnel of the company, effective January 7, 2023. Mr. Hemant Auti is a qualified company secretary having Membership no. A51703 and having over 5 years of versatile & diversified experience in Corporate Laws, Corporate actions, Secretarial and Legal Compliances of Listed Companies, Public and Private Companies as well. He currently is also pursuing LLB. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. 5 independent directors (7 non-independent directors). Independent Director Sandeep Joshi was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Nov 13
Second quarter 2023 earnings released: EPS: ₹1.98 (vs ₹1.72 in 2Q 2022) Second quarter 2023 results: EPS: ₹1.98 (up from ₹1.72 in 2Q 2022). Revenue: ₹1.15b (up 5.8% from 2Q 2022). Net income: ₹99.2m (up 15% from 2Q 2022). Profit margin: 8.6% (up from 7.9% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year and the company’s share price has also increased by 15% per year. Announcement • Oct 21
Anuh Pharma Limited Announces Resignation of Bharat Gangani as Company Secretary and Compliance Officer Anuh Pharma Limited announced that Mr. Bharat Gangani, has tendered his resignation on 20th October, 2022 from the post of Company Secretary and Compliance Officer of the Company due to personal reasons. The company has accepted his resignation and relived his with effect from the closing of business hours of 7th November, 2022. his successor shall be appointed shortly and the same shall be intimated to the Stock Exchange in due course. Announcement • Aug 06
Anuh Pharma Limited Approves Final Dividend for the Financial Year Ended 2021-2022 Anuh Pharma Limited announced that at the AGM held on August 5, 2022 approved Final Dividend of INR 1.75/- per Equity Share of the Company for the financial year ended 2021-2022. Valuation Update With 7 Day Price Move • Aug 02
Investor sentiment improved over the past week After last week's 15% share price gain to ₹105, the stock trades at a trailing P/E ratio of 17.2x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 99% over the past three years. Announcement • Jul 28
Anuh Pharma Limited to Report Q1, 2023 Results on Aug 05, 2022 Anuh Pharma Limited announced that they will report Q1, 2023 results on Aug 05, 2022 Upcoming Dividend • Jul 27
Upcoming dividend of ₹1.75 per share Eligible shareholders must have bought the stock before 03 August 2022. Payment date: 04 September 2022. Payout ratio is a comfortable 29% and this is well supported by cash flows. Trailing yield: 1.9%. Within top quartile of Indian dividend payers (1.7%). Higher than average of industry peers (1.0%). Reported Earnings • Jul 16
Full year 2022 earnings released Full year 2022 results: Revenue: ₹4.87b (up 13% from FY 2021). Net income: ₹305.6m (up 7.5% from FY 2021). Profit margin: 6.3% (down from 6.6% in FY 2021). Announcement • Jul 13
Anuh Pharma Limited, Annual General Meeting, Aug 05, 2022 Anuh Pharma Limited, Annual General Meeting, Aug 05, 2022, at 16:30 Indian Standard Time. Announcement • May 15
Anuh Pharma Limited Recommends Final Dividend for the Financial Year Ended 31 March 2022 Anuh Pharma Limited announced that at its board meeting held on May 14, 2022, approved recommended final dividend of INR 1.75 per equity share of face value of INR 5 each (that is 35%) for the financial year ended 31 March 2022, subject to the approval of the Shareholders at the upcoming Annual General Meeting of the company. Announcement • May 08
Anuh Pharma Limited to Report Q4, 2022 Results on May 14, 2022 Anuh Pharma Limited announced that they will report Q4, 2022 results on May 14, 2022 Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Director Sandeep Joshi was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Apr 06
Investor sentiment improved over the past week After last week's 16% share price gain to ₹101, the stock trades at a trailing P/E ratio of 22.4x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 60% over the past three years. Reported Earnings • Feb 05
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹1.49 (up from ₹0.83 in 3Q 2021). Revenue: ₹1.32b (up 34% from 3Q 2021). Net income: ₹74.5m (up 78% from 3Q 2021). Profit margin: 5.6% (up from 4.3% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 02
Anuh Pharma Limited to Report Q2, 2022 Results on Feb 04, 2022 Anuh Pharma Limited announced that they will report Q2, 2022 results on Feb 04, 2022 Reported Earnings • Nov 12
Second quarter 2022 earnings released: EPS ₹1.72 (vs ₹1.32 in 2Q 2021) The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2022 results: Revenue: ₹1.11b (down 1.4% from 2Q 2021). Net income: ₹86.0m (up 30% from 2Q 2021). Profit margin: 7.8% (up from 5.9% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Aug 10
Upcoming dividend of ₹1.50 per share Eligible shareholders must have bought the stock before 17 August 2021. Payment date: 18 September 2021. Trailing yield: 1.2%. Lower than top quartile of Indian dividend payers (1.4%). Higher than average of industry peers (0.7%). Reported Earnings • Jul 22
Full year 2021 earnings released: EPS ₹5.68 (vs ₹2.86 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹4.32b (up 41% from FY 2020). Net income: ₹284.4m (up 99% from FY 2020). Profit margin: 6.6% (up from 4.7% in FY 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • Jun 02
Insider recently sold ₹1.3m worth of stock On the 24th of May, Bijal Shroff sold around 11k shares on-market at roughly ₹127 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought ₹263k more than they sold in the last 12 months. Reported Earnings • May 23
Full year 2021 earnings released The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹4.42b (up 44% from FY 2020). Net income: ₹284.4m (up 99% from FY 2020). Profit margin: 6.4% (up from 4.7% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 22
Anuh Pharma Limited Recommends Final Dividend Anuh Pharma Limited recommended a final dividend of INR 1.50 per equity share of face value of INR 5 each (30%), subject to shareholders' approval in the forthcoming Annual General Meeting. Valuation Update With 7 Day Price Move • May 10
Investor sentiment improved over the past week After last week's 16% share price gain to ₹165, the stock trades at a trailing P/E ratio of 31x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 113% over the past three years. Valuation Update With 7 Day Price Move • Apr 24
Investor sentiment improved over the past week After last week's 22% share price gain to ₹139, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 79% over the past three years. Valuation Update With 7 Day Price Move • Apr 02
Investor sentiment improved over the past week After last week's 16% share price gain to ₹106, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 18x in the Pharmaceuticals industry in India. Total returns to shareholders of 27% over the past three years. Is New 90 Day High Low • Mar 01
New 90-day low: ₹109 The company is down 23% from its price of ₹142 on 01 December 2020. The Indian market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period. Reported Earnings • Feb 11
Third quarter 2021 earnings released: EPS ₹0.83 (vs ₹1.27 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₹983.3m (up 30% from 3Q 2020). Net income: ₹41.8m (down 34% from 3Q 2020). Profit margin: 4.3% (down from 8.4% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 10
New 90-day low: ₹115 The company is down 19% from its price of ₹143 on 12 November 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period. Announcement • Jan 30
Anuh Pharma Limited to Report Q3, 2021 Results on Feb 09, 2021 Anuh Pharma Limited announced that they will report Q3, 2021 results on Feb 09, 2021 Announcement • Jan 09
Anuh Pharma Limited Announces Executive Changes Anuh Pharma Limited announced that the following items were considered and approved:1)1. Appointment of Mr. Bipin N. Shah as a Non-Executive Director and Vice Chairman of the Company with effect from 08th January, 2021 2) The relinquishment of position of Managing Director by Mr. Bipin N. Shah for the purpose of Board Restructuring 3) The appointment and re-designation of Mr. Ritesh B. Shah and Mr. Vivek B. Shah as Joint Managing Directors from the position of Whole Time Directors & Chief Executive Officers with effect from 8th January, 2021. Is New 90 Day High Low • Dec 08
New 90-day low: ₹138 The company is down 28% from its price of ₹192 on 09 September 2020. The Indian market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 12% over the same period. 
